• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aerovate Therapeutics Inc (NQ: AVTE )

    1.870 +0.030 (+1.63%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 175,929
    Open 1.900
    Bid (Size) 1.790 (1)
    Ask (Size) 1.900 (55)
    Prev. Close 1.840
    Today's Range 1.830 - 1.910
    52wk Range 1.250 - 32.41
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q2 2024
    AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Aerovate Therapeutics to Explore Strategic Alternatives
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -91.43%
    -91.43%
    1 Month
    -1.06%
    -1.06%
    3 Month
    -89.06%
    -89.06%
    6 Month
    -90.47%
    -90.47%
    1 Year
    -88.02%
    -88.02%

    More News

    Read More
    The 3 Hottest Stock Downgrades From Last Week
    Via InvestorPlace
    Nasdaq Surges Over 200 Points; Aaron's Shares Jump
    Via Benzinga
    Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Crude Oil Rises 1%; Mustang Bio Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Why 90% Of Aerovate Therapeutics' Value Just Went Up In Smoke
    Via Investor's Business Daily
    Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday?
    Via Benzinga
    US Stocks Mixed; Dow Tumbles Over 100 Points
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Recap: Aerovate Therapeutics Q4 Earnings
    Via Benzinga
    Recap: Aerovate Therapeutics Q3 Earnings
    Via Benzinga
    Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    AVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q4 2023
    Via InvestorPlace
    Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
    From Aerovate Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.